Teva Pharmaceutical Industries Ltd (TEVA) stock
TEVANYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 7/30127% above fair value
$42.57−1.93 (-4.34%)
Close on Nov 16, 2026Market cap $49.61BP/E 71.0Yield –
Teva Pharmaceutical Industries operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Teva Pharmaceutical Industries's operating cash flow for the twelve months ending Jun 30, 2026 was $1.90B, up 36.5% year over year. For fiscal 2025 it was $1.65B, up 32.2% from the year before. Over ten years it grew -11.4% a year on average. The highest annual figure on record is $5.54B in fiscal 2015.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.65B | +32.2% |
| FY2024 | Dec 31, 2024 | $1.25B | -8.8% |
| FY2023 | Dec 31, 2023 | $1.37B | -14.0% |
| FY2022 | Dec 31, 2022 | $1.59B | +99.2% |
| FY2021 | Dec 31, 2021 | $798.00M | -34.4% |
| FY2020 | Dec 31, 2020 | $1.22B | +62.6% |
| FY2019 | Dec 31, 2019 | $748.00M | -69.4% |
| FY2018 | Dec 31, 2018 | $2.45B | +9.9% |
| FY2017 | Dec 31, 2017 | $2.23B | -42.8% |
| FY2016 | Dec 31, 2016 | $3.89B | -29.8% |
| FY2015 | Dec 31, 2015 | $5.54B | +8.1% |
| FY2014 | Dec 31, 2014 | $5.13B | +58.4% |
| FY2013 | Dec 31, 2013 | $3.24B | -29.2% |
| FY2012 | Dec 31, 2012 | $4.57B | +10.6% |
| FY2011 | Dec 31, 2011 | $4.13B | -0.0% |
| FY2010 | Dec 31, 2010 | $4.14B | +22.6% |
| FY2009 | Dec 31, 2009 | $3.37B | +4.4% |
| FY2008 | Dec 31, 2008 | $3.23B | +78.2% |
| FY2007 | Dec 31, 2007 | $1.81B | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $411.00M | +81.1% |
| Q1 FY2026 | Mar 31, 2026 | -$40.00M | – |
| Q4 FY2025 | Dec 31, 2025 | $1.16B | +101.4% |
| Q3 FY2025 | Sep 30, 2025 | $369.00M | -46.8% |
| Q2 FY2025 | Jun 30, 2025 | $227.00M | +120.4% |
| Q1 FY2025 | Mar 31, 2025 | -$105.00M | – |
| Q4 FY2024 | Dec 31, 2024 | $575.00M | -51.4% |
| Q3 FY2024 | Sep 30, 2024 | $693.00M | +13760.0% |
| Q2 FY2024 | Jun 30, 2024 | $103.00M | -68.2% |
| Q1 FY2024 | Mar 31, 2024 | -$124.00M | – |
| Q4 FY2023 | Dec 31, 2023 | $1.18B | +21.7% |
| Q3 FY2023 | Sep 30, 2023 | $5.00M | -99.1% |
| Q2 FY2023 | Jun 30, 2023 | $324.00M | +163.4% |
| Q1 FY2023 | Mar 31, 2023 | -$145.00M | – |
| Q4 FY2022 | Dec 31, 2022 | $973.00M | +113.4% |
| Q3 FY2022 | Sep 30, 2022 | $543.00M | +2.6% |
| Q2 FY2022 | Jun 30, 2022 | $123.00M | -43.6% |
| Q1 FY2022 | Mar 31, 2022 | -$49.00M | – |
| Q4 FY2021 | Dec 31, 2021 | $456.00M | +37.8% |
| Q3 FY2021 | Sep 30, 2021 | $529.00M | +72.3% |
| Q2 FY2021 | Jun 30, 2021 | $218.00M | -20.1% |
| Q1 FY2021 | Mar 31, 2021 | -$405.00M | -232.8% |
| Q4 FY2020 | Dec 31, 2020 | $331.00M | -38.5% |
| Q3 FY2020 | Sep 30, 2020 | $307.00M | -5.5% |
| Q2 FY2020 | Jun 30, 2020 | $273.00M | – |
| Q1 FY2020 | Mar 31, 2020 | $305.00M | +172.3% |
| Q4 FY2019 | Dec 31, 2019 | $538.00M | +46.6% |
| Q3 FY2019 | Sep 30, 2019 | $325.00M | -22.8% |
| Q2 FY2019 | Jun 30, 2019 | -$227.00M | -240.1% |
| Q1 FY2019 | Mar 31, 2019 | $112.00M | -92.5% |
| Q4 FY2018 | Dec 31, 2018 | $367.00M | -57.3% |
| Q3 FY2018 | Sep 30, 2018 | $421.00M | -47.0% |
| Q2 FY2018 | Jun 30, 2018 | $162.00M | -62.8% |
| Q1 FY2018 | Mar 31, 2018 | $1.50B | +1000.0% |
| Q4 FY2017 | Dec 31, 2017 | $859.00M | +854.4% |
| Q3 FY2017 | Sep 30, 2017 | $795.00M | -45.6% |
| Q2 FY2017 | Jun 30, 2017 | $435.00M | – |
| Q1 FY2017 | Mar 31, 2017 | $136.00M | – |
| Q4 FY2016 | Dec 31, 2016 | $90.00M | – |
| Q3 FY2016 | Sep 30, 2016 | $1.46B | – |
See a number that looks wrong?